Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...